Fresenius Kabi introduces generic Faslodex
Fresenius Kabi is offering fulvestrant injection in a 250mg per 5mL prefilled syringe.
Fresenius Kabi developed its fulvestrant injection prefilled syringe to be stable at room temperature, making it the only form of fulvestrant injection to require no refrigeration. This can help pharmacists save on the limited refrigeration space available to them, the company said.
The product is a generic of AstraZeneca’s Faslodex.
“Fresenius Kabi is pleased to continue the expansion of our oncology portfolio by offering Fulvestrant injection,” said John Ducker, Fresenius Kabi USA president and CEO. “We are pleased to be the only company offering this product in a room temperature stable formulation to assist clinicians in managing their costs and workflow.”
Fulvestrant Injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy; HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy; HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine therapy or following disease progression on endocrine therapy; HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemacicilib in women with disease progression after endocrine therapy.